(NASDAQ: IVVD) Invivyd's forecast annual revenue growth rate of 51.73% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.35%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.04%.
Invivyd's revenue in 2026 is $55,866,000.On average, 5 Wall Street analysts forecast IVVD's revenue for 2026 to be $19,021,624,746, with the lowest IVVD revenue forecast at $15,215,296,466, and the highest IVVD revenue forecast at $22,457,926,066. On average, 5 Wall Street analysts forecast IVVD's revenue for 2027 to be $26,914,747,600, with the lowest IVVD revenue forecast at $15,301,911,057, and the highest IVVD revenue forecast at $35,482,521,519.
In 2028, IVVD is forecast to generate $62,023,706,870 in revenue, with the lowest revenue forecast at $37,647,886,291 and the highest revenue forecast at $96,451,533,710.